Healthcare provider profile · identity verified

Ashok Kumar, M.D.

Internal Medicine · HAWTHORNE, CA · NPI 1518963032

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	368	91
Atorvastatin Calcium	Atorvastatin Calcium	350	92
Losartan Potassium	Losartan Potassium	297	87
Chlorhexidine Gluconate	Chlorhexidine Gluconate	214	12
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	197	17
Pantoprazole Sodium	Pantoprazole Sodium	195	83
Albuterol Sulfate Hfa	Albuterol Sulfate	189	61
Furosemide	Furosemide	159	45
Eliquis	Apixaban	157	19
Omeprazole	Omeprazole	151	34
Gabapentin	Gabapentin	142	38
Levothyroxine Sodium	Levothyroxine Sodium	134	25
Hydralazine Hcl	Hydralazine Hcl	133	37
Prednisone	Prednisone	118	68
Famotidine	Famotidine	115	27
Metoprolol Tartrate	Metoprolol Tartrate	111	42
Hydrochlorothiazide	Hydrochlorothiazide	105	29
Carvedilol	Carvedilol	104	28
Potassium Chloride	Potassium Chloride	94	27
Metformin Hcl	Metformin Hcl	80	25
Clonidine Hcl	Clonidine Hcl	77	28
Montelukast Sodium	Montelukast Sodium	71	28
Levetiracetam	Levetiracetam	66	15
Levofloxacin	Levofloxacin	62	57
Clopidogrel	Clopidogrel Bisulfate	58	21
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	56	17
Triamcinolone Acetonide	Triamcinolone Acetonide	53	12
Tamsulosin Hcl	Tamsulosin Hcl	48	17
Lactulose	Lactulose	45	suppressed
Memantine Hcl	Memantine Hcl	45	suppressed
Glipizide	Glipizide	44	15
Enoxaparin Sodium	Enoxaparin Sodium	42	suppressed
Ventolin Hfa	Albuterol Sulfate	42	14
Metoclopramide Hcl	Metoclopramide Hcl	39	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Lisinopril	Lisinopril	38	12
Januvia	Sitagliptin Phosphate	37	suppressed
Ertapenem	Ertapenem Sodium	36	13
Sodium Chloride	0.9 % Sodium Chloride	36	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	34	11
Risperidone	Risperidone	34	suppressed
Tradjenta	Linagliptin	34	suppressed
Latanoprost	Latanoprost	32	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	32	suppressed
Mirtazapine	Mirtazapine	31	suppressed
Tramadol Hcl	Tramadol Hcl	31	13
Fluticasone Propionate	Fluticasone Propionate	30	suppressed
Amiodarone Hcl	Amiodarone Hcl	28	suppressed
Linzess	Linaclotide	28	suppressed
Budesonide	Budesonide	27	suppressed
Diltiazem Hcl	Diltiazem Hcl	27	suppressed
Duloxetine Hcl	Duloxetine Hcl	27	suppressed
Epogen	Epoetin Alfa	27	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	27	suppressed
Finasteride	Finasteride	27	suppressed
Ipratropium Bromide	Ipratropium Bromide	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	11
Advair Hfa	Fluticasone Propion/Salmeterol	26	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	24	20
Donepezil Hcl	Donepezil Hcl	24	suppressed
Lansoprazole	Lansoprazole	24	suppressed
Nystatin	Nystatin	24	suppressed
Ibuprofen	Ibuprofen	23	suppressed
Azithromycin	Azithromycin	22	21
Cefepime Hcl	Cefepime Hcl	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	21	13
Midodrine Hcl	Midodrine Hcl	21	suppressed
Modafinil	Modafinil	21	suppressed
Novolog Flexpen	Insulin Aspart	21	suppressed
Acetylcysteine	Acetylcysteine	20	suppressed
Simvastatin	Simvastatin	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Humalog	Insulin Lispro	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	12
Divalproex Sodium	Divalproex Sodium	18	suppressed
Benztropine Mesylate	Benztropine Mesylate	17	suppressed
Celecoxib	Celecoxib	17	suppressed
Labetalol Hcl	Labetalol Hcl	17	suppressed
Levemir Flexpen	Insulin Detemir	17	suppressed
Scopolamine	Scopolamine	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Atenolol	Atenolol	16	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Breyna	Budesonide/Formoterol Fumarate	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	13
Incruse Ellipta	Umeclidinium Bromide	15	suppressed
Ivermectin	Ivermectin	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Permethrin	Permethrin	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Brilinta	Ticagrelor	13	suppressed
Digoxin	Digoxin	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Nuplazid	Pimavanserin Tartrate	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	suppressed
Clonazepam	Clonazepam	12	suppressed
Clonidine	Clonidine	12	suppressed
Methimazole	Methimazole	12	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	11	suppressed
Daptomycin	Daptomycin	11	suppressed
Haloperidol	Haloperidol	11	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Ozempic	Semaglutide	11	suppressed
Procto-Med Hc	Hydrocortisone	11	suppressed
Spironolactone	Spironolactone	11	suppressed
Ssd	Silver Sulfadiazine	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error